Peter Lim

1.3k total citations · 2 hit papers
37 papers, 885 citations indexed

About

Peter Lim is a scholar working on Reproductive Medicine, Surgery and Obstetrics and Gynecology. According to data from OpenAlex, Peter Lim has authored 37 papers receiving a total of 885 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Reproductive Medicine, 18 papers in Surgery and 16 papers in Obstetrics and Gynecology. Recurrent topics in Peter Lim's work include Endometrial and Cervical Cancer Treatments (14 papers), Ovarian cancer diagnosis and treatment (13 papers) and Uterine Myomas and Treatments (13 papers). Peter Lim is often cited by papers focused on Endometrial and Cervical Cancer Treatments (14 papers), Ovarian cancer diagnosis and treatment (13 papers) and Uterine Myomas and Treatments (13 papers). Peter Lim collaborates with scholars based in United States, Canada and Spain. Peter Lim's co-authors include E.Y. Kang, Kathleen N. Moore, Ana Oaknin, Bradley J. Monk, Susana Banerjee, Domenica Lorusso, Jason Konner, Jiao Wang, Raymond A. Lee and Michael J. Birrer and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Gynecologic Oncology.

In The Last Decade

Peter Lim

31 papers receiving 859 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I

2021 186 citations Kathleen N. Moore, Ana Oaknin et al. profile →
Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer

2023 81 citations Lucy Gilbert, Ana Oaknin et al. Gynecologic Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter Lim United States	13	438	364	341	339	103	37	885
Roberta Tana Italy	17	330 0.8×	399 1.1×	183 0.5×	205 0.6×	81 0.8×	22	803
Stephen Dobbs United Kingdom	9	994 2.3×	557 1.5×	205 0.6×	657 1.9×	106 1.0×	16	1.2k
D. Smaniotto Italy	19	209 0.5×	541 1.5×	361 1.1×	486 1.4×	265 2.6×	50	1.0k
Andreas duBois Germany	9	400 0.9×	125 0.3×	291 0.9×	171 0.5×	105 1.0×	15	713
G. P. Breitbach Germany	10	413 0.9×	239 0.7×	222 0.7×	330 1.0×	105 1.0×	36	685
Mivael Olivera Peru	10	140 0.3×	385 1.1×	481 1.4×	232 0.7×	150 1.5×	31	852
J.Taylor Wharton United States	15	399 0.9×	417 1.1×	217 0.6×	394 1.2×	119 1.2×	36	898
G.A. Rawlings Canada	15	255 0.6×	440 1.2×	138 0.4×	494 1.5×	143 1.4×	21	876
M. Valeria Cáceres Argentina	5	119 0.3×	316 0.9×	378 1.1×	194 0.6×	119 1.2×	12	668
Max Buttarelli France	16	161 0.4×	313 0.9×	224 0.7×	447 1.3×	64 0.6×	50	777

Countries citing papers authored by Peter Lim

Since Specialization

Citations

This map shows the geographic impact of Peter Lim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Lim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Lim more than expected).

Fields of papers citing papers by Peter Lim

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Lim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Lim. The network helps show where Peter Lim may publish in the future.

Co-authorship network of co-authors of Peter Lim

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Lim. A scholar is included among the top collaborators of Peter Lim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Lim. Peter Lim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tinker, Anna V., et al.. (2025). Long-Term Toxicities of Adolescent and Young Adults Who Underwent Radiation Therapy for Cervix Cancer: A Cross-Sectional Analysis. Journal of Adolescent and Young Adult Oncology. 14(5). 392–400.

Leitão, Mario M., Kristin Bixel, Dana M. Chase, et al.. (2025). ROCC/GOG-3043: a randomized controlled trial of robotic versus open surgery for early-stage cervical cancer. International Journal of Gynecological Cancer. 35(7). 101760–101760. 2 indexed citations

Fuh, Katherine C., Thomas Reid, Ugo De Giorgi, et al.. (2024). AXLerate-OC/GOG-3059/ENGOT OV-66: Results of a phase 3, randomized, double-blind, placebo/paclitaxel-controlled study of batiraxcept (AVB-S6-500) in combination with paclitaxel in patients with platinum-resistant recurrent ovarian cancer.. Journal of Clinical Oncology. 42(17_suppl). LBA5515–LBA5515. 4 indexed citations

Ng, Joseph, Mario M. Leitão, Peter Lim, Tae‐Joong Kim, & Sang Wun Kim. (2024). Asian Society for Gynecologic Robotic Surgery consensus guidelines on robotic surgery in gynecological cancer. 5(1). 8–19.

Lim, Lauren, April Slee, & Peter Lim. (2024). Feasibility and early oncologic outcomes of Total Intracorporeal Robotic Radical Hysterectomy with Vaginal Cerclage (TIRRHVC) for the treatment of clinical stage IB cervical cancer: A tumor containment technique. Gynecologic Oncology Reports. 54. 101437–101437.

Gilbert, Lucy, Ana Oaknin, Ursula A. Matulonis, et al.. (2023). Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. Gynecologic Oncology. 170. 241–247. 81 indexed citations breakdown →

O’Malley, David M., Ana Oaknin, Ursula A. Matulonis, et al.. (2022). O011/#496 Mirvetuximab soravtansine and bevacizumab in folate receptor αlpha-positive ovarian cancer: efficacy in patients with and without prior bevacizumab. A7.2–A8. 2 indexed citations

Lim, Peter, et al.. (2022). Unconventional Obturator Artery Nutrient Branch: Image of an Anatomical Variation. Diagnostics. 12(8). 2019–2019. 1 indexed citations

Paek, Jiheum & Peter Lim. (2021). The early surgical period in robotic radical hysterectomy is related to the recurrence after surgery in stage IB cervical cancer. International Journal of Medical Sciences. 18(12). 2697–2704. 5 indexed citations

10.

Kang, E.Y., et al.. (2020). Factors in the feasibility and safety of outpatient robotic-assisted hysterectomy for endometrial or cervical carcinoma. Gynecologic Oncology. 157(2). 482–486. 13 indexed citations

11.

Paek, Jiheum, E.Y. Kang, & Peter Lim. (2019). Comparative analysis of genitourinary function after type C1 robotic nerve-sparing radical hysterectomy versus type C2 robotic radical hysterectomy. Surgical Oncology. 30. 58–62. 10 indexed citations

12.

Tinker, Anna V., Peter Lim, Christina Aquino‐Parsons, et al.. (2019). Phase I (safety assessment) of durvalumab (MEDI4736) with focal sensitizing radiotherapy in platinum resistant ovarian, primary peritoneal or fallopian tube epithelial carcinoma.. Journal of Clinical Oncology. 37(15_suppl). TPS5604–TPS5604. 1 indexed citations

13.

Tse, Ka Yu, Hys Ngan, & Peter Lim. (2017). Robot-assisted gynaecological cancer surgery—complications and prevention. Best Practice & Research Clinical Obstetrics & Gynaecology. 45. 94–106. 10 indexed citations

14.

Lim, Peter & E.Y. Kang. (2017). How to prepare the patient for robotic surgery: before and during the operation. Best Practice & Research Clinical Obstetrics & Gynaecology. 45. 32–47. 5 indexed citations

15.

Lim, Peter, et al.. (2016). Multicenter analysis comparing robotic, open, laparoscopic, and vaginal hysterectomies performed by high‐volume surgeons for benign indications. International Journal of Gynecology & Obstetrics. 133(3). 359–364. 73 indexed citations

16.

Lim, Peter, et al.. (2011). Robot-assisted total intracorporeal low anterior resection with primary anastomosis and radical dissection for treatment of stage IV endometriosis with bowel involvement: morbidity and its outcome. Journal of Robotic Surgery. 5(4). 273–278. 13 indexed citations

17.

Lim, Peter, et al.. (2010). A comparative detail analysis of the learning curve and surgical outcome for robotic hysterectomy with lymphadenectomy versus laparoscopic hysterectomy with lymphadenectomy in treatment of endometrial cancer: A case-matched controlled study of the first one hundred twenty two patients. Gynecologic Oncology. 120(3). 413–418. 132 indexed citations

18.

Lim, Peter, et al.. (2010). Learning Curve and Surgical Outcome for Robotic-Assisted Hysterectomy with Lymphadenectomy: Case-Matched Controlled Comparison with Laparoscopy and Laparotomy for Treatment of Endometrial Cancer. Journal of Minimally Invasive Gynecology. 17(6). 739–748. 83 indexed citations

19.

Lim, Peter. (2009). Robotic assisted total pelvic exenteration: A case report. Gynecologic Oncology. 115(2). 310–311. 38 indexed citations

20.

Brander, Victoria A. & Peter Lim. (1992). The Shoulder in Rheumatoid Arthritis. Journal of Back and Musculoskeletal Rehabilitation. 2(2). 46–52. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact